Yep and interesting they kept right on buying post “no clinical benefit” announcement of March/April? from memory that saw the SP fall of a cliff. This is evident in the last couple of substantial holder anns so the majority sellers in that crises were the twitchy retail holders.
Regardless of this however we really need to see the marking passed as another rejection will do more damage than the last as the market would interpret it as there being something terminally wrong with the submission, most likely the small number of patients in the data set or other. Especially given the recent inference by the company that bsi now see things more positively.
It’s worth noting that while CE mark award provides a temporary SP lift without subsequent news regarding commercial deals or other positive news flowing from the mark it can decline just a quickly and be back to where it was. SVA is a prime recent example of this.
OSL Price at posting:
17.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)